Introduction
Bladder cancer (BCa), a prevalent malignant tumor in the urinary system,1 poses significant health challenges. For non-muscle-invasive bladder cancer and cases with high risks of recurrence and progression, postoperative…

Bladder cancer (BCa), a prevalent malignant tumor in the urinary system,1 poses significant health challenges. For non-muscle-invasive bladder cancer and cases with high risks of recurrence and progression, postoperative…

Recent remarks from MarketAxess Holdings (MKTX) at the Barclays Financial Services Conference put a spotlight on its next phase of growth, including deeper automation, non U.S. credit expansion and emerging markets opportunities.
See our latest analysis for MarketAxess Holdings.
Even with these growth levers, the 1 year total shareholder return of negative 29.18 percent and 3 year total shareholder return of negative 38.11 percent show longer term momentum has faded, despite a modest recent recovery in the 30 day share price return of 3.88 percent from a last close of 167.24 dollars.
If you like the MarketAxess story but want more ideas in financial technology, this could be a good moment to explore fast growing stocks with high insider ownership.
With revenues and profits still growing, but the share price languishing well below past highs and roughly 20 percent under the average analyst target, is MarketAxess now a mispriced compounder, or is the market correctly discounting its future growth?
With MarketAxess last closing at 167.24 dollars, the most followed narrative points to a materially higher fair value anchored around future earnings power.
The analysts have a consensus price target of 218.833 dollars for MarketAxess Holdings based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of 274.0 dollars, and the most bearish reporting a price target of just 168.0 dollars.
Read the complete narrative.
Curious how a steady revenue glide path, rising margins and a premium earnings multiple combine into that fair value? The narrative lifts the lid on those projections, but keeps the boldest assumptions just out of view until you dive in.
Result: Fair Value of $200.90 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, that upside case could unravel if competitive pressure intensifies and high grade block trades remain stubbornly phone based, limiting electronic share gains.
Find out about the key risks to this MarketAxess Holdings narrative.
Step away from analyst targets and the picture looks quite different. On a price to earnings basis of 28.3 times versus a fair ratio of 14.9 times, and above both industry and peer averages, MarketAxess screens as expensive. Is the market overpaying for quality, or just pricing in reality?
See what the numbers say about this price — find out in our valuation breakdown.


Toxoplasmosis, caused by the protozoan parasite Toxoplasma gondii [T. gondii], is a widespread zoonotic infection affecting approximately one-third of the global population, with varying prevalence based on geographic location,…

The Guardian has learned that couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ. But what is polygenic screening and does it work?

The phenomenon around weight loss jabs is “transformational”, says James O’Loan, boss of…

Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on…

November was packed with high horology moments the world over. In Geneva, the Grand Prix d’Horlogerie de Genève gathered once again to honour the year’s best watches, while in Dubai, retailer Ahmed Seddiqi & Sons organised the most…

Have you ever wondered why your energy drops in the afternoon or why you can’t lose those extra pounds? People don’t realise that their food choices can harm their metabolism. Think of your metabolism as an engine; it powers your body and…

The Clinical Practice Research Datalink (CPRD) offers access to two medical databases, CPRD Aurum and CPRD GOLD, containing deidentified primary care electronic health records of patients from a network of general practitioners…